Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    "Cold agglutinin disease"
Show Display Options
Rank Status Study
1 Completed Therapy for Chronic Cold Agglutinin Disease
Condition: Cold Agglutinin Disease
Interventions: Drug: Rituximab;   Drug: Fludarabine
2 Completed Therapy of Chronic Cold Agglutinin Disease With Eculizumab
Condition: Cold Agglutinin Disease
Intervention: Drug: Eculizumab
3 Recruiting Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease
Conditions: Cold Agglutinin Disease;   Autoimmune Hemolytic Anemia
Intervention: Drug: Bendamustine, Rituximab
4 Active, not recruiting Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
Condition: Refractory Cold Agglutinin Disease
Intervention: Drug: Bortezomib
5 Recruiting Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders
Conditions: Bullous Pemphigoid (BP);   Cold Agglutinin Disease;   Warm Autoimmune Hemolytic Anemia;   End-stage Renal Disease (ESRD)
Interventions: Drug: TNT009;   Other: Placebo
6 Completed The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
Conditions: Pemphigus;   Auto-immune Thrombocytopenic Purpura;   Hemolytic Auto-immune Anaemia;   Cold Agglutinin Disease;   Cryoglobulinemia
Intervention: Drug: Rituximab (MABTHERA® or RITUXAN®).

Indicates status has not been verified in more than two years